Brandon M Huffman

21PUBLICATIONS
164CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Education assessment and evaluation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Feb 13, 2026
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.

Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun

|Sep 02, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

Rishi Surana, Micaela Morgado, Ashwin Somasundaram

|Dec 06, 2024
Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.

Eric Michael Lander, Vasily N Aushev, Brandon M Huffman

|Sep 30, 2024
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer.

Brandon M Huffman, Osama E Rahma, Kevin Tyan

|Sep 16, 2024
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.

Harshabad Singh, Joanne Xiu, Kevin S Kapner

|Jul 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.

Paul E Oberstein, Andressa Dias Costa, Emily A Kawaler

Pageof 4

Frequent Collaborators

9 joint publications

James M Cleary

8 joint publications

Harshabad Singh

7 joint publications

Douglas A Rubinson

7 joint publications

Brian M Wolpin